Loading...
XSHE300584
Market cap337mUSD
Dec 31, Last price  
20.16CNY
1D
-0.77%
1Q
-11.59%
IPO
74.89%
Name

Nanjing Hicin Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300584 chart
P/E
66.62
P/S
4.67
EPS
0.30
Div Yield, %
0.27%
Shrs. gr., 5y
—
Rev. gr., 5y
-6.17%
Revenues
518m
-1.64%
147,952,995169,502,080197,655,207220,993,472280,827,571455,034,585711,907,833924,537,940706,295,710578,315,038526,465,340517,832,190
Net income
36m
+11.92%
25,592,00933,287,33734,214,07340,328,96045,236,37765,600,50583,223,21197,258,20755,230,052285,878,18232,448,86736,315,554
CFO
24m
045,164,66524,293,22753,902,47537,737,79046,557,48177,210,75497,277,03973,388,59359,940,771023,932,692
Dividend
Jun 18, 20240.05 CNY/sh
Earnings
May 15, 2025

Profile

Nanjing Hicin Pharmaceutical Co., Ltd. engages in the research, development, manufacture, marketing, and sale of pharmaceutical preparations and synthetic chemicals in China. The company offers antivirals, antibiotics, endocrine drugs, gastrointestinal drugs, orthopedic drugs, drugs for cardio-cerebral system, and immuno-modulate agents. It also provides technical transferring services. The company also exports APIs; omeprazole sodium and cefepime hydrochloride for injections; and lansoprazole tablets to South-Asian countries, South-American countries, and European countries. Nanjing Hicin Pharmaceutical Co., Ltd. was founded in 2003 and is based in Nanjing, China.
URL
https://www.hicin.cn/page1/index1
IPO date
Jan 12, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
517,832
-1.64%
526,465
-8.97%
Cost of revenue
415,588
433,442
Unusual Expense (Income)
NOPBT
102,244
93,023
NOPBT Margin
19.74%
17.67%
Operating Taxes
1,374
Tax Rate
1.34%
NOPAT
100,870
93,023
Net income
36,316
11.92%
32,449
-88.65%
Dividends
(6,465)
(30,000)
Dividend yield
0.23%
0.78%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
252,983
178,153
Long-term debt
Deferred revenue
6,480
8,479
Other long-term liabilities
1
Net debt
59,369
(124,069)
Cash flow
Cash from operating activities
23,933
CAPEX
(197,222)
Cash from investing activities
(137,266)
29,118
Cash from financing activities
65,071
FCF
(84,502)
(120,967)
Balance
Cash
46,822
95,068
Long term investments
146,791
207,154
Excess cash
167,722
275,899
Stockholders' equity
777,211
740,281
Invested Capital
1,079,237
835,430
ROIC
10.54%
12.97%
ROCE
8.10%
8.24%
EV
Common stock shares outstanding
120,012
120,000
Price
23.28
-27.70%
32.20
61.00%
Market cap
2,793,874
-27.69%
3,864,000
61.00%
EV
2,853,243
3,739,931
EBITDA
155,804
141,167
EV/EBITDA
18.31
26.49
Interest
8,335
7,253
Interest/NOPBT
8.15%
7.80%